Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
Bullboard Posts
User Avatar Image
(50)
•••
Post by farmerjaneon Jun 03, 2014 11:37am
169 Views
Post# 22624871

ALS

ALS New patent Publication date April 29, 2014, Filing date Dec 24, 2010.... Original Assignee- Amorfix Life Sciences Ltd. Title: Methods and compositions to treat and detect misfolded- SOD1 mediated diseases. US 8709422 B2

The invention provides a method for treating a medical condition, disease or disorder mediated gby a misfolded form of superoxide dismutase (SOD1) in a subject in need of treatment. In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or ALS. The invention also provides antibodies that bind to monomeric or misfolded SOD1 and not on the molecular surface of native homodimeric SOD1.

In addition the invention includes methods of identifying substances for the treatment or prevention of Alzheimer's, Parkinson's Disease or ALS and kits using the binding proteins of the invention.

What's it going to be Biogen ?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities